Abstract: A method of generating a soft sensor for a mechanical system includes defining a training dataset of sensor values received from at least one first sensor corresponding a first physical quantity. The method further includes training a Sparse Identification of Nonlinear Dynamics (SINDy) model using the training dataset to generate a mathematical function defining a relationship between the sensor values and soft sensor values corresponding to a second physical quantity. The method further includes embedding machine readable instructions based on the mathematical function into an embedded system of the mechanical system including at least one first sensor. The machine readable instructions, when executed by the embedded system, cause the embedded system to receive sensor values corresponding to the first physical quantity and generate soft sensor values based on the sensor values and the mathematical function.

Abstract: The method of the present invention refers to digital link. The method (101) identifies the user interaction (103) with a specific object (100). According to this interaction, the method (101) identifies characteristics or data on the specific object (100) which allow the method (101) to extract personal information and associate it with an output message (for example, a predefined text, audio message to be recorded, etc.) that will be sent to the target contact/user (102) (which can be another person, a group of people, a system/service, or objects in general). Since the contact target (102) is identified, a smart device associated with the method (101) triggers a preset action for the connection with the contact target (102). The method (101) allows the reception of target responses contact (102) enabling the user (103) to maintain communication with the target user (102).

Abstract: The method of the present invention refers to digital link. The method (101) identifies the user interaction (103) with a specific object (100). According to this interaction, the method (101) identifies characteristics or data on the specific object (100) which allow the method (101) to extract personal information and associate it with an output message (for example, a predefined text, audio message to be recorded, etc.) that will be sent to the target contact/user (102) (which can be another person, a group of people, a system/service, or objects in general). Since the contact target (102) is identified, a smart device associated with the method (101) triggers a preset action for the connection with the contact target (102). The method (101) allows the reception of target responses contact (102) enabling the user (103) to maintain communication with the target user (102).

Abstract: Disclosed is a process for obtaining a solid catalyst component for ethylene polymerization and copolymerization, wherein a carrier of particulate silica (65 to 85% by weight) is impregnated with a catalytically active portion (15 to 35% by weight) including titanium, magnesium, chlorine, alkoxy groups and at least one organometallic compound of the groups 1, 2, 12 or 13 of the periodic table. Further, the invention refers to the solid catalyst component thus obtained and to a process for ethylene polymerization and copolymerization wherein is used said catalyst. The catalyst obtained is suitable for the production of ethylene homo- and copolymers as narrow molecular weight distribution high density polyethylene (NMWHDPE) and linear low density polyethylene (LLDPE) with controlled morphology and improved structure.

Abstract: The present invention relates to a process for obtaining a catalyst of high activity based on a mixture of supports, more specifically, the mixture of supports being Al2O3 plus MgCl2, intended for the production of polyolefins. The catalyst of the present invention involves the use of a spherical support based on special alumina that serves as a porous matrix, which is impregnated, by precipitation, with magnesium chloride by dissolving the latter in ethers and/or alcohols.

Abstract: The present invention relates to compounds derived from taurine with non-steroidal anti inflammatory activity. In a first embodiment, the present invention relates to compounds derived from taurine, in which taurine is bound directly by means of an amide bond or through an spacing group, to a compound selected from the group of non-steroidal anti inflammatory compounds, cited as derived from taurine presenting the Formula (I): in which R means the component with non-steroidal anti inflammatory activity. In a second embodiment, the invention provides a process for obtaining the compounds of Formula (I) by reaction of taurine with a compound belonging to the group of non-steroidal anti inflammatory (NSAIs), in order to obtain a compound derived from taurine by direct bond or through a spacing group of the taurine to the NSAI. The invention also relates to the pharmaceutical compositions comprising at least one compound derived from taurine presenting non-steroidal anti inflammatory activity.

Abstract: Preparation and use of phthalimide and/or sulphonamide derivatives with nitric oxide donor properties, having activities in increasing gamma-globin gene expression and anti-inflammatory and analgesic activities, effective in the treatment of hematologic diseases which require reducing the TNF-? levels and an exogenous source of nitric oxide, such as sickle-cell disease. The functionalized phthalimide derivatives are designed from the prototypes thalidomide and hydroxyurea.

Abstract: Preparation and use of phthalimide and/or sulphonamide derivatives with nitric oxide donor properties, having activities in increasing gamma-globin gene expression and anti-inflammatory and analgesic activities, effective in the treatment of hematologic diseases which require reducing the TNF-? levels and an exogenous source of nitric oxide, such as sickle-cell disease. The functionalized phthalimide derivatives are designed from the prototypes thalidomide and hydroxyurea.

Abstract: Preparation and use of phthalimide and/or sulphonamide derivatives with nitric oxide donor properties, having activities in increasing gamma-globin gene expression and anti-inflammatory and analgesic activities, effective in the treatment of hematologic diseases which require reducing the TNF-? levels and an exogenous source of nitric oxide, such as sickle-cell disease. The functionalized phthalimide derivatives are designed from the prototypes thalidomide and hydroxyurea.

Abstract: Disclosed is a process for obtaining a solid catalyst component for ethylene polymerization and copolymerization, wherein a carrier of particulate silica (65 to 85% by weight) is impregnated with a catalytically active portion (15 to 35% by weight) including titanium, magnesium, chlorine, alkoxy groups and at least one organometallic compound of the groups 1, 2, 12 or 13 of the periodic table. Further, the invention refers to the solid catalyst component thus obtained and to a process for ethylene polymerization and copolymerization wherein is used said catalyst. The catalyst obtained is suitable for the production of ethylene homo- and copolymers as narrow molecular weight distribution high density polyethylene (NMWHDPE) and linear low density polyethylene (LLDPE) with controlled morphology and improved structure.

Abstract: Preparation and use of phthalimide and/or sulphonamide derivatives with nitric oxide donor properties, having activities in increasing gamma-globin gene expression and anti-inflammatory and analgesic activities, effective in the treatment of hematologic diseases which require reducing the TNF-? levels and an exogenous source of nitric oxide, such as sickle-cell disease. The functionalized phthalimide derivatives are designed from the prototypes thalidomide and hydroxyurea.

Abstract: The present invention relates to phthalimide derivatives of non-steroidal and/or TNF-? modulating anti-inflammatory compounds as well as the process of obtaining the so-called derivatives, pharmaceutical compositions containing such derivatives and their uses, including use in the treatment of inflammatory diseases, especially those related to chronic inflammatory processes, such as rheumatoid arthritis and intestinal inflammatory diseases (for instance, Chron's disease) and the use of the referred to pharmaceutical compositions as antipyretic, analgesic and platelet antiaggregating medications.

Abstract: The present invention relates to a process for obtaining a catalyst of high activity based on a mixture of supports, more specifically, the mixture of supports being Al2O3 plus MgCl2, intended for the production of polyolefins. The catalyst of the present invention involves the use of a spherical support based on special alumina that serves as a porous matrix, which is impregnated, by precipitation, with magnesium chloride by dissolving the latter in ethers and/or alcohols.

Abstract: The present invention relates to compounds derived from taurine with non-steroidal anti inflammatory activity. In a first embodiment, the present invention relates to compounds derived from taurine, in which taurine is bound directly by means of an amide bond or through an spacing group, to a compound selected from the group of non-steroidal anti inflammatory compounds, cited as derived from taurine presenting the Formula (I): in which R means the component with non-steroidal anti inflammatory activity. In a second embodiment, the invention provides a process for obtaining the compounds of Formula (I) by reaction of taurine with a compound belonging to the group of non-steroidal anti inflammatory (NSAIs), in order to obtain a compound derived from taurine by direct bond or through a spacing group of the taurine to the NSAI. The invention also relates to the pharmaceutical compositions comprising at least one compound derived from taurine presenting non-steroidal anti inflammatory activity.

Abstract: The present invention refers to the use of phthalimide and/or sulphonamide derivatives with nitric oxide donor properties, which have important activities in increasing the gamma-globin gene expression and anti-inflammatory and analgesic activities, effective in the treatment of hematologic diseases which require reducing the TNF-? levels and an exogenous source of nitric oxide. More particularly, the present invention describes the use of such phthalimide and/or sulphonamide derivatives for the treatment of sickle-cell disease. The invention also has as a novel characteristic the disclosure of new functionalized phthalimide derivatives designed from the prototypes thalidomide and hydroxyurea, and designed rationally through the strategy of molecular hybridization for the treatment of said diseases.